Zephyr AI

Zephyr AI is a precision medicine company that applies state-of-the-art machine learning to large-scale, real-world data, transforming fragmented clinical and biological information into actionable insights. The company serves biopharma and diagnostics partners across the full therapeutic lifecycle—from drug discovery and patient stratification to clinical translation and diagnostic innovation—delivering interpretable AI models that reduce risk, accelerate development, and scale with confidence.

Founded by a team of scientists, engineers, clinicians, business leaders, and innovators, Zephyr AI is united by a shared mission to make precision medicine more effective and accessible. The company provides access to one of the world's largest multimodal clinicogenomic datasets, enabling partners to explore populations, accelerate discovery, and improve trial success—all without requiring new assays or disrupting existing workflows.

Platform and Core Technology

• Zephyr AI's multi-modal AI platform transforms fragmented, multi-modal data into actionable insights designed to integrate directly into R&D and clinical workflows.
• The platform applies advanced machine learning to enterprise-scale real-world data, turning noise into signal and complexity into clarity across the therapeutic lifecycle.
• Models are interpretable and support discovery, validation, and deployment stages, helping partners move faster and reduce development risk.
• The AI is built on three core principles: learn from a lot, refine with a little, and enrich limited patient data with deep biological context—enabling meaningful insights even from sparse clinical inputs.
• By imbuing rich biological context into routine clinical inputs, Zephyr's tools deliver clinically actionable outputs that lay the foundation for more effective, personalized treatment.

Partnering Model and Applications

• Zephyr AI collaborates with biopharma and diagnostics companies to fine-tune its multi-modal AI for new drugs or diagnostics, integrating seamlessly into existing workflows with no new assays required.
• Partnership applications span drug discovery, patient stratification, diagnostic innovation, and clinical translation.
• The company's real-world data assets and AI models help partners accelerate development timelines, reduce risk, and deliver precision medicine solutions at scale.
• Zephyr's approach supports both population-scale insights and patient-level precision, bridging the gap between large-scale data analysis and individualized treatment decisions.

Mission, Vision, and Guiding Principles

• Zephyr AI's mission is to transform precision medicine with AI-enabled software that integrates seamlessly into existing workflows for rapid validation and clinical translation.
• The company's vision is a future where precision medicine is accessible, immediate, and effective—where every patient's treatment decisions are guided by robust, biologically grounded insights tailored to their unique disease biology.
• Zephyr is committed to expanding access to precision medicine by designing AI that works with the limited clinical data available today while delivering powerful, actionable outputs.

Leadership Team

• Allen Chao, Ph.D., Chief Executive Officer — Founder of Watson Pharmaceuticals (later Allergan plc, acquired by AbbVie), which grew to approximately $2.8 billion in annual revenue under his leadership. A cancer survivor and lifelong champion for cancer patients, Dr. Chao earned his Ph.D. in Industrial and Physical Pharmacy from Purdue University and brings deep expertise in business development, strategic execution, and pharmaceutical operations. The Chao family helped establish the Chao Family Comprehensive Cancer Center at UC Irvine.
• Jeff Sherman, MSCS, Co-Founder and Chief Technology Officer — Leads the architecture of Zephyr AI's secure, scalable AI and data platforms. Previously a Machine Learning Architect at Rally Health (acquired by UnitedHealth Group), where he led deployment of a large-scale recommendation engine using healthcare and behavioral data. Earlier work at BBN Technologies spanned DARPA/IARPA programs in natural language processing, computer vision, sensor fusion, and graph mining. Also a Founding Partner at Red Cell Partners and Co-Founder of Adaje Inc. Holds an MS in Computer Science from the University of Pennsylvania.
• Anshu Jain, MD, Chief Business and Clinical Officer — A double board-certified radiation oncologist and clinical informatician who leads business development, clinical strategy, medical affairs, and partner collaborations. Previously served as Chief Medical Officer at Aster Insights, and translates Zephyr's AI and real-world data capabilities into solutions for biopharma and diagnostic partners.

Zephyr AI combines enterprise-scale real-world data, advanced multi-modal machine learning, and deep biological expertise to redefine how therapies are developed, validated, and matched to patients—bringing clarity to complexity and meaningful impact to patients and partners alike.